Publication Name	World Journal of Hepatology
Manuscript ID	12944
Country	Taiwan

Received	2014-07-29 20:38
Peer-Review Started	2014-07-30 16:14
To Make the First Decision	2014-12-17 11:21
Return for Revision	2014-12-26 11:52
Revised	2015-01-05 15:13
Second Decision	2015-07-21 19:25
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-07-27 17:25
Articles in Press	2015-07-27 17:25
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-07-29 15:48
Publish the Manuscript Online	2015-08-08 14:17

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Optimal combination of antiangiogenic therapy for hepatocellular carcinoma
Manuscript Source	Invited Manuscript
All Author List	Hui-Ju Ch’ang
Funding Agency and Grant Number	Funding Agency Grant Number National Health Research Institutes, Taiwan
Corresponding Author	Hui-Ju Ch’ang, MD, National Institute of Cancer Research, National Health Research Institutes, R1-2034, 35, Keyen Road, Miaoli 35053, Taiwan. hjmc@nhri.org.tw
Key Words	Antiangiogenesis; Hepatocellular carcinoma; Biomarker; Cytokines; Dynamic contrast enhanced magnetic resonance imaging
Core Tip	Antiangiogenic therapy has become an important component of treatment in hepatocellular carcinoma (HCC) patients. However, traditional anatomic imaging of tumor shrinkage is not appropriate to evaluate the efficacy of antiangiogenesis achieved by normalizing tumor vasculature and systemic suppression of angiogenic and inflammatory cytokines. To identify and validate potential response biomarkers, standardized systemic, circulating, tissue and imaging assays should be incorporated in to preclinical and clinical studies regarding the combination of antiangiogenic agents to cytotoxic or biologic agents. The optimal dosage, schedule and duration of antiangiogenic during com-bination therapy for HCC patients should be titrated according to these response biomarkers.
Publish Date	2015-08-08 14:17
Citation	Ch’ang HJ. Optimal combination of antiangiogenic therapy for hepatocellular carcinoma. World J Hepatol 2015; 7(16): 2029-2040
URL	http://www.wjgnet.com/1948-5182/full/v7/i16/2029.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i16.2029

Full Article (PDF)	WJH-7-2029.pdf
Full Article (Word)	WJH-7-2029.doc
Manuscript File	12944-Review.doc
Answering Reviewers	12944-Answering reviewers.pdf
Audio Core Tip	12944-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	12944-Conflict-of-interest statement.pdf
Copyright License Agreement	12944-Copyright assignment.pdf
Peer-review Report	12944-Peer-review(s).pdf
Scientific Misconduct Check	12944-Scientific misconduct check.pdf
Scientific Editor Work List	12944-Scientific editor work list.pdf